Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009289
Filing Date
2025-05-08
Accepted
2025-05-08 16:40:42
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 652998
2 EX-10.4 ex10-4.htm EX-10.4 441863
3 EX-31.1 ex31-1.htm EX-31.1 17148
4 EX-31.2 ex31-2.htm EX-31.2 9383
5 EX-32.1 ex32-1.htm EX-32.1 4538
6 EX-32.2 ex32-2.htm EX-32.2 4595
  Complete submission text file 0001641172-25-009289.txt   4554783

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE cing-20250331.xsd EX-101.SCH 38693
8 XBRL CALCULATION FILE cing-20250331_cal.xml EX-101.CAL 52919
9 XBRL DEFINITION FILE cing-20250331_def.xml EX-101.DEF 137361
10 XBRL LABEL FILE cing-20250331_lab.xml EX-101.LAB 322484
11 XBRL PRESENTATION FILE cing-20250331_pre.xml EX-101.PRE 251054
70 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 503934
Mailing Address 1901 W. 47TH PLACE KANSAS CITY KS 66205
Business Address 1901 W. 47TH PLACE KANSAS CITY KS 66205 (913) 942-2300
Cingulate Inc. (Filer) CIK: 0001862150 (see all company filings)

EIN.: 863825535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40874 | Film No.: 25926968
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)